'What Else Don't We Know?' May Spread Beyond Valeant
This article was originally published in Scrip
The day after a damning report from short-selling firm Citron Research sent shares of Valeant Pharmaceuticals International Inc. into tailspin, diving 40%, the stock spiraled down again, plunging 20% – this time pushed off the cliff by BMO Nesbitt Burns Inc. analyst Alex Arfaei, who started off the day by asking "What else is out there that we don't know?"
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.